Dexamethasone Administration in 1st Episode of Febrile Urinary Tract Infection

Summary

Hypothesis: Administration of corticoids (dexamethasone) together with the conventional antibiotherapy in the acute phase of a febrile urinary tract infection could reduce the risk of renal scarring after 6 months of the primo-infection.

Primary objectives:To evaluate the reduction in incidence of renal scarring after 6 months of a acute pyelonephritis between the control group (conventional therapy plus placebo) and intervention group (conventional therapy plus dexamethasone.

Design: Multicentre randomized clinical trial,placebo controled, including children between 2 months and 14 years with a acute pyelonephritis proven by a acute phase DMSA (dimethylsuccinic acid ). A total of 180 children in to parallel groups (intervention and placebo) will be included.

Conditions

• Acute Pyelonephritis

Sponsors & Collaborators

• Hospital Universitari Sant Joan de Reus

  collaborator OTHER

• Hospital Universitari Joan XXIII de Tarragona.

  collaborator OTHER

• Pius Hospital de Valls

  collaborator UNKNOWN

• Hospital Arnau de Vilanova

  collaborator OTHER

• Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

  collaborator OTHER

• Maternal-Infantil Vall d´Hebron Hospital

  collaborator OTHER

• Hospital General Universitario Santa Lucía

  collaborator OTHER

• University Rovira i Virgili

  collaborator OTHER

• Institut Investigacio Sanitaria Pere Virgili

  lead OTHER

Principal Investigators

• Escribano J Joaquin, PhD MD · IISPV- URV-Hospital Universitari Sant Joan de Reus- Research unit in pediatrics, nutrition and human development

• Closa R Ricardo, MD PhD · IISPV-URV- Hospital Universitari Joan XXIII de Tarragona-Research unit in pediatrics, nutrition and human development

• Ferré N Natalia, PhD · IISPV-URV-Research unit in pediatrics, nutrition and human development

• Ibars Z Zaira, MD PhD · HOSPITAL ARNAU DE VILANOVA DE LLEIDA

• Maria Gloria MG Fraga, MD PhD · HOSPITAL DE LA SANTA CREU I SANT PAU, DE BARCELONA

• Madrid A Alvaro, MD PhD · HOSPITAL MATERNOINFANTIL VALL D'HBRON, BARCELONA

• Samper M Manuel, MD PhD · Pius Hospital de Valls

• Gonzalez JD Juan David, MD PhD · HOSPITAL GENERAL UNIVERSITARIO SANTA LUCÍA DE CARTAGENA

• Parada E Esther, MD PhD · HOSPITAL JOAN XXII DE TARRAGONA

Eligibility

Min Age

2 Months

Max Age

14 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2013-04-30

Primary Completion

2016-05-31

Completion

2019-06-30

Countries

• Spain

Study Locations